Literature DB >> 9563735

Nosocomial pneumonia in patients with acute respiratory distress syndrome.

J Chastre1, J L Trouillet, A Vuagnat, M L Joly-Guillou, H Clavier, M C Dombret, C Gibert.   

Abstract

To describe the epidemiologic and microbial aspects of ventilator-associated pneumonia (VAP) in patients with acute respiratory distress syndrome (ARDS), we prospectively evaluated 243 consecutive patients who required mechanical ventilation (MV) for > or = 48 h, 56 of whom developed ARDS as defined by a Murray lung injury score > 2.5. We did this with bronchoscopic techniques when VAP was clinically suspected, before any modification of existing antimicrobial therapy. For all patients, the diagnosis of pneumonia was established on the basis of culture results of protected-specimen brush (PSB) (> or = 10(3) cfu/ml) and bronchoalvelolar lavage fluid (BALF) (> or = 10(4) cfu/ml) specimens, and direct examination of cells recovered by bronchoalveolar lavage (BAL) (< or = 5% of infected cells). Thirty-one (55%) of the 56 patients with ARDS developed VAP for a total of 41 episodes, as compared with only 53 (28%) of the 187 patients without ARDS for a total of 65 episodes (p = 0.0005). Only 10% of first episodes of VAP in patients with ARDS occurred before Day 7 of MV, as compared with 40% of the episodes in patients without ARDS (p = 0.005). All but two patients with ARDS who developed VAP had received antimicrobial treatment (mostly with broad-spectrum antibiotics) before the onset of infection, as compared with only 35 patients without ARDS (p = 0.004). The organisms most frequently isolated from patients with ARDS and VAP were methicillin-resistant Staphylococcus aureus (23%), nonfermenting gram-negative bacilli (21%), and Enterobacteriaceae (21%). These findings confirm that microbiologically provable VAP occurs far more often in patients with ARDS than in other ventilated patients. Because these patients are often treated with antibiotics early in the course of the syndrome, the onset of VAP is frequently delayed after the first week of MV, and is then caused mainly by methicillin-resistant S. aureus and other multiresistant microorganisms.

Entities:  

Mesh:

Year:  1998        PMID: 9563735     DOI: 10.1164/ajrccm.157.4.9708057

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  43 in total

Review 1.  Acute respiratory distress syndrome and nosocomial pneumonia.

Authors:  T T Bauer; A Torres
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

Review 2.  The microbiome and critical illness.

Authors:  Robert P Dickson
Journal:  Lancet Respir Med       Date:  2015-12-12       Impact factor: 30.700

3.  Candida pneumonia in the ICU: myth or reality?

Authors:  Jean-Damien Ricard; Damien Roux
Journal:  Intensive Care Med       Date:  2009-06-27       Impact factor: 17.440

Review 4.  [Nosocomial pneumonia from a radiological perspective].

Authors:  P Agarwal; A Wielandner
Journal:  Radiologe       Date:  2017-01       Impact factor: 0.635

Review 5.  Antibacterial treatment of invasive mechanical ventilation-associated pneumonia.

Authors:  F Barcenilla; E Gascó; J Rello; L Alvarez-Rocha
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

7.  Impact of selective digestive decontamination on respiratory tract Candida among patients with suspected ventilator-associated pneumonia. A meta-analysis.

Authors:  J C Hurley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-26       Impact factor: 3.267

8.  Flexible fiberoptic bronchoscopy and remifentanil target-controlled infusion in ICU: a preliminary study.

Authors:  Ludivine Chalumeau-Lemoine; Annabelle Stoclin; Valérie Billard; Agnès Laplanche; Bruno Raynard; François Blot
Journal:  Intensive Care Med       Date:  2012-09-28       Impact factor: 17.440

9.  Pseudomonas aeruginosa induces localized immunosuppression during pneumonia.

Authors:  Maureen H Diaz; Ciara M Shaver; John D King; Srinidhi Musunuri; Jeffrey A Kazzaz; Alan R Hauser
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

10.  Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome.

Authors:  Robert P Dickson; Benjamin H Singer; Michael W Newstead; Nicole R Falkowski; John R Erb-Downward; Theodore J Standiford; Gary B Huffnagle
Journal:  Nat Microbiol       Date:  2016-07-18       Impact factor: 17.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.